MBRX logo

Moleculin Biotech (MBRX) Cash From Financing

Annual CFF

$4.65 M
+$4.67 M+20321.74%

December 31, 2023

Summary

Performance

1-Year Change

+20321.74%

3-Year Change

-79.37%

5-Year Change

-61.39%

15-Year Change

-53.76%

MBRX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

47.55%
MBRX annual cash flow from financing activities is higher than 47.55% of companies in Healthcare sector

High & Low

All-time High

$74.72 M
MBRX annual cash flow from financing activities is currently -93.78% below its historical high of $74.72 million

3-Year Low

-$23.00 K

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
MBRX previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 21, 2025
MBRX next annual earnings announcement is scheduled for Mar 21, 2025

OtherMBRXcash flowmetrics:

Annual CFI

-$124.00 K
MBRX annual cash flow from investing activities is -$124.00 thousand

Annual CFO

-$24.10 M
MBRX annual cash flow from operations is -$24.10 million

Annual FCF

-$24.23 M
MBRX annual free cash flow is -$24.23 million

Annual CAPEX

-
MBRX annual capital expenditures value is unknown

Quarterly CFF

$4.66 M
+$4.68 M+18736.00%

September 30, 2024

Summary

Performance

3-Month Change

+18736%

1-Year Change

+100%

3-Year Change

+9408.16%

5-Year Change

+9408.16%

MBRX Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

79.68%
MBRX quarterly cash flow from financing activities is higher than 79.68% of companies in Healthcare sector

High & Low

All-time High

$74.75 M
MBRX quarterly cash flow from financing activities is currently -93.77% below its historical high of $74.75 million

3-Year Low

-$25.00 K

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
MBRX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 21, 2025
MBRX next earnings announcement is scheduled for Mar 21, 2025

OtherMBRXcash flowmetrics:

Quarterly CFI

$0.00
MBRX quarterly cash flow from investing activities is $0.00

Quarterly CFO

-$6.11 M
MBRX quarterly cash flow from operations is -$6.11 million

Quarterly FCF

-$6.11 M
MBRX quarterly free cash flow is -$6.11 million

Quarterly CAPEX

-
MBRX quarterly capital expenditures value is unknown

TTM CFF

$9.10 M
+$4.66 M+105.12%

September 30, 2024

Summary

Performance

3-Month Change

+105.12%

1-Year Change

+101.75%

3-Year Change

+4983.24%

5-Year Change

+4983.24%

MBRX TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

51.84%
MBRX TTM cash flow from financing activities is higher than 51.84% of companies in Healthcare sector

High & Low

All-time High

$92.01 M
MBRX TTM cash flow from financing activities is currently -90.11% below its historical high of $92.01 million

3-Year Low

-$36.00 K

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
MBRX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 21, 2025
MBRX next earnings announcement is scheduled for Mar 21, 2025

OtherMBRXcash flowmetrics:

TTM CFI

-$94.00 K
MBRX TTM cash flow from investing activities is -$94.00 thousand

TTM CFO

-$24.19 M
MBRX TTM cash flow from operations is -$24.19 million

TTM FCF

-$24.28 M
MBRX TTM free cash flow is -$24.28 million

TTM CAPEX

-
MBRX TTM capital expenditures value is unknown

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

MBRX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+10000.0%+100.0%+101.8%
3 y3 years-79.4%+9408.2%+4983.2%
5 y5 years-61.4%+9408.2%+4983.2%

MBRX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-93.8%>+9999.0%at high>+9999.0%-87.8%>+9999.0%
5 y5-year-93.8%>+9999.0%-93.8%>+9999.0%-90.1%>+9999.0%
alltimeall time-93.8%>+9999.0%-93.8%>+9999.0%-90.1%>+9999.0%

Moleculin Biotech Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
$4.66 M(<-9900.0%)
$9.10 M(+105.1%)
Jun 2024
-
-$25.00 K(<-9900.0%)
$4.44 M(-1.6%)
Mar 2024
-
$0.00(-100.0%)
$4.51 M(-3.0%)
Dec 2023
$4.65 M(<-9900.0%)
$4.46 M(<-9900.0%)
$4.65 M(+2400.5%)
Sep 2023
-
-$4000.00(-108.2%)
$186.00 K(+3.9%)
Jun 2023
-
$49.00 K(-65.2%)
$179.00 K(+51.7%)
Mar 2023
-
$141.00 K(>+9900.0%)
$118.00 K(-613.0%)
Dec 2022
-$23.00 K(-100.0%)
$0.00(-100.0%)
-$23.00 K(0.0%)
Sep 2022
-
-$11.00 K(-8.3%)
-$23.00 K(-36.1%)
Jun 2022
-
-$12.00 K(<-9900.0%)
-$36.00 K(+50.0%)
Mar 2022
-
$0.00(0.0%)
-$24.00 K(-100.0%)
Dec 2021
$74.72 M(+231.4%)
$0.00(-100.0%)
$74.72 M(-6.8%)
Sep 2021
-
-$24.00 K(<-9900.0%)
$80.21 M(-2.2%)
Jun 2021
-
$0.00(-100.0%)
$81.99 M(-10.9%)
Mar 2021
-
$74.75 M(+1263.0%)
$92.01 M(+308.0%)
Dec 2020
$22.55 M
$5.48 M(+211.2%)
$22.55 M(+32.1%)
Sep 2020
-
$1.76 M(-82.4%)
$17.07 M(+11.1%)
DateAnnualQuarterlyTTM
Jun 2020
-
$10.01 M(+89.2%)
$15.36 M(-25.5%)
Mar 2020
-
$5.29 M(>+9900.0%)
$20.62 M(-1.1%)
Dec 2019
$20.85 M(+73.1%)
$0.00(-100.0%)
$20.85 M(-7.8%)
Sep 2019
-
$52.00 K(-99.7%)
$22.61 M(+0.2%)
Jun 2019
-
$15.28 M(+176.8%)
$22.56 M(+141.3%)
Mar 2019
-
$5.52 M(+213.5%)
$9.35 M(-22.4%)
Dec 2018
$12.04 M(+19.7%)
$1.76 M(>+9900.0%)
$12.04 M(+3.2%)
Sep 2018
-
$0.00(-100.0%)
$11.67 M(-8.5%)
Jun 2018
-
$2.07 M(-74.8%)
$12.75 M(-2.0%)
Mar 2018
-
$8.21 M(+493.6%)
$13.01 M(+29.3%)
Dec 2017
$10.06 M(+13.5%)
$1.38 M(+27.8%)
$10.06 M(+15.9%)
Sep 2017
-
$1.08 M(-53.5%)
$8.68 M(+14.3%)
Jun 2017
-
$2.33 M(-55.8%)
$7.59 M(-44.1%)
Mar 2017
-
$5.26 M(>+9900.0%)
$13.58 M(+53.2%)
Dec 2016
$8.87 M
$3000.00(>+9900.0%)
$8.87 M(+0.0%)
Sep 2016
-
$0.00(-100.0%)
$8.86 M(0.0%)
Jun 2016
-
$8.31 M(+1405.4%)
$8.86 M(+1505.4%)
Mar 2016
-
$552.00 K
$552.00 K

FAQ

  • What is Moleculin Biotech annual cash flow from financing activities?
  • What is the all time high annual CFF for Moleculin Biotech?
  • What is Moleculin Biotech annual CFF year-on-year change?
  • What is Moleculin Biotech quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Moleculin Biotech?
  • What is Moleculin Biotech quarterly CFF year-on-year change?
  • What is Moleculin Biotech TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Moleculin Biotech?
  • What is Moleculin Biotech TTM CFF year-on-year change?

What is Moleculin Biotech annual cash flow from financing activities?

The current annual CFF of MBRX is $4.65 M

What is the all time high annual CFF for Moleculin Biotech?

Moleculin Biotech all-time high annual cash flow from financing activities is $74.72 M

What is Moleculin Biotech annual CFF year-on-year change?

Over the past year, MBRX annual cash flow from financing activities has changed by +$4.67 M (+20321.74%)

What is Moleculin Biotech quarterly cash flow from financing activities?

The current quarterly CFF of MBRX is $4.66 M

What is the all time high quarterly CFF for Moleculin Biotech?

Moleculin Biotech all-time high quarterly cash flow from financing activities is $74.75 M

What is Moleculin Biotech quarterly CFF year-on-year change?

Over the past year, MBRX quarterly cash flow from financing activities has changed by +$4.66 M (+100.00%)

What is Moleculin Biotech TTM cash flow from financing activities?

The current TTM CFF of MBRX is $9.10 M

What is the all time high TTM CFF for Moleculin Biotech?

Moleculin Biotech all-time high TTM cash flow from financing activities is $92.01 M

What is Moleculin Biotech TTM CFF year-on-year change?

Over the past year, MBRX TTM cash flow from financing activities has changed by +$4.59 M (+101.75%)